News · 26 weeks44+700%
2025-12-142026-06-07
Mix3890d
- SEC Filings23(61%)
- Other8(21%)
- Offering4(11%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form S-8 filed by Nanobiotix S.A.S-8 - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Provides First Quarter 2026 Operational and Financial UpdateCompleted a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J sponsored NANORAY-312 study eliminating the previously planned interim analysis and modifying the final analysis to include fewer events and to be conducted soonerPresented
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Joins the Euronext Tech Leaders IndexPARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Closing of Global OfferingPARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the "Closing") of its global offering (the "Global Offering"), including in respect of the earlier total exercise by the underwriters of their option (the "Option") to purchase additional new ordinary shares in the form of additional American Depositary Shares (the "Additional ADSs"). Following the full exercise of the Option, the total number of ordinary shares (e
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form FWP filed by Nanobiotix S.A.FWP - Nanobiotix S.A. (0001760854) (Subject)
- SECSEC Form 424B5 filed by Nanobiotix S.A.424B5 - Nanobiotix S.A. (0001760854) (Filer)
- PRNANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 MillionPARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces that the underwriters of its previously announced global offering (the "Global Offering") have fully exercised their option to purchase 33,805 additional new ordinary shares in the form of additional American Depositary Shares (the "Additional ADSs") (the "Option"). Each Additional ADS represents one ordinary share, €0.03 nominal value per share (each an "Ordinary Share"), of the Comp
- SECSEC Form FWP filed by Nanobiotix S.A.FWP - Nanobiotix S.A. (0001760854) (Subject)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext ParisPARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time). Trading of the ordinary shares of the Company was halted at the request of the Company on May 21, 2026 from 9:00 a.m. CEST in the context of the previously announced offering consisting of (i) a public offering of its American Depo
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext ParisPARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares ("ADSs"), each ADS represent
- PRNanobiotix Announces Launch of Global Follow-On OfferingPARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately $87 million) consisting of (i) a public offering of its American Depositary Shares ("ADSs"), each ADS representing one ordinary share, €0.03 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "U.S. Offering
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 424B5 filed by Nanobiotix S.A.424B5 - Nanobiotix S.A. (0001760854) (Filer)
- SECSEC Form 6-K filed by Nanobiotix S.A.6-K - Nanobiotix S.A. (0001760854) (Filer)
- PRNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerPARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer ("NSCLC"), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response in Patients with Stage III Un
- PRNanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer StudyPARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study. This protocol amendment, submitted by NANORAY-312 global sponsor Johnson & Johnson, eliminates the previously planned interim analysis and modifies the final analysis to include fewer events than originally planned and to be conducted sooner. In Nanobiotix's view, this decision could accelerate and expand t
NBTX FAQ
7 questionsWhat does Nanobiotix S.A. do?
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small...Where does NBTX stock trade?
Nanobiotix S.A. (NBTX) is listed on NASDAQ.What sector and industry is NBTX in?
Nanobiotix S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nanobiotix S.A. go public?
Nanobiotix S.A. (NBTX) completed its IPO in 2020.What are analysts saying about NBTX?
Nanobiotix S.A. has had 3 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-02-06. Recent price targets range from $1100.00 to $1200.00.What companies are similar to NBTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NBTX side-by-side with any of them on Quantisnow.How can I track NBTX on Quantisnow?
Quantisnow aggregates Nanobiotix S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBTX to receive live email and push alerts on every new disclosure.